A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms MODERATO
- Sponsors Sanofi
- 19 Jun 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
- 19 Jun 2009 Actual patient number (331) added as reported by ClinicalTrials.gov.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.